# Sildenafil and Uteroplacental Perfusion

> **NCT01107782** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Tehran University of Medical Sciences** · enrollment: 70 (estimated)

## Conditions studied

- Fetal Growth Retardation

## Interventions

- **DRUG:** sildenafil
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01107782
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-06
- **Primary completion:** 2010-06
- **Final completion:** 2012-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2011-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01107782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01107782, "Sildenafil and Uteroplacental Perfusion". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01107782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*